Alchemix is an exemplar of a class of anthraquinone with efficacy against multidrug resistant tumors. We have explored further the mechanism of action of alchemix and investigated the effect of extending its side arm bearing the alkylating functionality with regard to DNA binding and activity against multidrug resistant cancer cells. Increasing the distance between the intercalating chromophore and the alkylating functionality of ICT2901 (propyl), ICT2902
anthraquinone pharmacophore, which is a prerequisite for topo II poisoning [1] . Substantial work has defined the relationship between the basic aminoalkylamino sidechains and configuration of functional groups attached to the 1,4-disubstituted pharmacophore of mitoxantrone [1] [2] [3] [4] [5] [6] [7] . The clinical success of the anthraquinone-based anticancer drugs is tempered by their failure in tumors that express the ABCB1 (MDR1) gene [8] [9] [10] , or exhibit downregulation/mutation [11] or phosphorylation [12] of topo II. In an attempt to overcome these resistance mechanisms, we have previously reported 1,4-disubstituted chloroethylaminoanthraquinones as a hybrid class of agents containing DNA intercalating and alkylating functionalities [13, 14] , of which one agent, alchemix ( Figure 1 ) possesses substantial anticancer activity against doxorubicin-(A2780AD) and cisplatin-resistant (A2780/cp70) tumor xenografts in mice [15] . In particular, symmetrical (two identical sidechains) 1,4-disubstituted anthraquinones with alkylating groups on both sidechains lose cytotoxic potency in multidrug-resistant (MDR) cancer cells, but non-symmetrical mixed sidechain-configured anthraquinones, typified by alchemix, remain effective against such malignant cells [14, 15] .
Figure 1
This study expands the knowledge of the DNA binding properties of alchemix and its cellular pharmacology. To explore these phenomena, three novel analogues of alchemix were prepared ( Figure 1 ), which would provide a platform for a better understanding of the optimum requirements for DNA adduct formation, topo IIα inhibition and cytotoxicity.
Materials and methods

Synthesis of target compounds
The synthesis of alchemix and the three novel anthraquinones was carried out using methodology previously reported [13] . Briefly, ipso-substitution of 1-(2-(dimethylamino)ethylamino)-4-fluoro-5,8-dihydroxyanthracene-9,10-dione with the respective bis(hydroxyl)-aminoalkylamine generated bis-substituted hydroxyethyl precursors, which were converted to the target chloro compounds using triphenylphosphine-carbon tetrachloride complex (PPh 3 -CCl 4 ). Full experimental methodology and characterisation of ICT2901, ICT2902 and ICT2903 can be found in supporting information. All compounds were stored as hydrochloride salts at -20 °C under anhydrous conditions prior to use.
DNA binding studies
Doxorubicin, mechlorethamine (N-methyl-N,N-bis(2-chloroethyl)amine), 3-(4,5-simethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT), ammonium persulphate (APS), and sequagel 6 (concentrate) were obtained from Sigma-Aldrich Chemicals (Gillingham, U.K.).
Plasmid DNA pBR322 (0.25 U/µL) was purchased from New England Biolabs (Herts, U.K.), γ 32 P-ATP (500 Ci/mmol), 5´-TATGCGACTCCTGCATTAGG-3´ primer (10 pm/µl), dNTP mix (2.5 mM), T4 polynucleotide kinase (5 U/µl), bacterial alkaline phosphatase (BAP) (150 U/µl), Taq DNA polymerase (5 U/µl) and Hind III (15 U/µl), BamH1 and SalI restriction enzymes were purchased from Promega, (Southampton, UK). BIO-RAD spin columns were obtained from BIO-RAD Laboratories, (Beckenham, UK).
Taq polymerase stop assay
This experiment has previously been described [13, 16] . Briefly, the following constituents were added to a PCR tube: 0.2 % gelatine (5 µl), 25 mM MgCl 2 (10 µl), 10 × Taq polymerase buffer buffer (10 µl), 2.5 mM dNTP mix (10 µl), dH 2 O (8 µl) and 0.5µg drug-treated (1-100 nM) linearised pBR322 DNA (50 µl). The latter was generated after incubation for 1 h at 37 Step 2-4 were repeated 29 times before denaturing at 94 °C for 5 min followed by 10 min at 25 °C. The samples were then transferred into sterile eppendorf vials and the DNA precipitated with 3 volumes of ethanol (95 %, 300 µl) and NaOAc (3 M, 2 µl), vortexed and cooled in dry ice bath for 10 min before being centrifuged at 13,000 rpm for 10 min. The supernatant was removed and the samples were washed with ethanol (70 %, 150 µl), vortexed, centrifuged at 13,000 rpm for 10 min and the supernatant removed. The wash was repeated and the samples lyophilized. Each dried sample was re-suspended in formamide dye (4 µl), heated to 95 °C for 3 min and cooled in an ice-bath to denature the DNA. The samples were loaded into the wells of a 6% denaturing polyacrylamide gel and electrophoresis was performed in TBE buffer at 1600-2000 V (approx. 2-3 h, 55 °C) using vertical glass electrophoresis plates. The resulting gel was then transferred onto a Whatman 3MM filter paper and one layer of DE81, covered in film wrap and dried on a BIO-RAD 583 gel drier for approximately two h. Once dry, the gel was exposed to a Kodak Hyperfilm for 24 h before development.
UV thermal melting studies of ligands and calf thymus DNA
The protocol used to determine thermal denaturation profiles for double-stranded calf thymus (CT) DNA and ligand-induced melting temperature shifts (∆T m ) has been previously described [17, 18] . CT DNA (sodium salt) was purchased from Sigma and used without further purification; the buffer used was aqueous sodium phosphate (Na 2 HPO 4 /NaH 2 PO 4 10 mM, Na 2 EDTA 1 mM, pH 7.00), CT DNA solutions were quantitated spectrophotometrically using 
Chemosensitivity
All drugs were dissolved in DMSO to obtain stock solutions at 10 mM, aliquoted and stored Chemosensitivity was determined using the MTT assay 4 days later. For both 1 h and continuous drug exposures, MTT (20 µl, 5mg/ml) was added to each well and the plates incubated at 37 °C for 4 h. All medium was removed and formazan crystals were dissolved in 150 µl of DMSO. The absorbance of the resulting solution was measured at 540 nm using a multiwell spectrophotometer (Multiskan EX; Thermo Fisher Scientific, Waltham, MA, USA).
Survival and chemosensitivity were expressed as IC 50 values. All experiments were repeated in triplicate. Vials were placed on ice before analysis. Flow cytometry analyses were performed using a FACS-Calibur flow cytometer (BD Biosciences; San Jose, CA, USA). Data obtained from 10,000 cellular events were analyzed using the CellQuest software (BD Biosciences; San Jose, CA, USA).
γH2AX and cell cycle analysis
Induction of cellular apoptosis and necrosis
HCT116
p53+/+ colorectal carcinoma cells were exposed to drug concentrations equal to the IC 80 value for 1 h, followed by removal of the drug and recovery in fresh medium for 24 h. were rinsed an additional three times in water followed by addition of 200 µl 1% acetic acid/50% ethanol added to each well for incubation for 30 min. Finally, absorbance was measured at 540 nm and data analysed as previously described [20] .
Studies in Chinese Hamster Ovary (CHO) cell lines
Results
DNA sequence-selective alkylation and inter-strand cross-linking experiments
Compounds ICT2901, ICT2902 and ICT2903 were compared with alchemix for their ability to covalently adduct double-stranded DNA using the Taq polymerase stop assay [16] .
Inhibition of DNA elongation, consistent with DNA alkylation, was detected down to 5 nM for ICT2902 and ICT2903 compared with 1 µM for mechlorethamine ( Figure 2) . The four alkylating anthraquinones demonstrated a strong preference for guanines, specifically the guanines that were flanked by a 5'-cytosine and a 3'-guanine residue (e.g. 5'-CGG; positions 536, 586 and 596 in Figure 2 ) and to a lesser extent at the second guanine in the same sequence (5'-CGG; positions 537, 587 and 597). A potentially important alkylation site was also observed at position 529 in the sequence 5'-CGT, which was not an alkylation site shared by mechlorethamine. In contrast, mechlorethamine showed a pattern of sequence selective alkylation as observed previously, with a preference for reaction within runs of contiguous guanines [21] . For example, alkylation was observed at 5'-TGGGC, which was not a target site for any of the four anthraquinones, suggesting that the 5'-TG or 5'-GG residue is not an ideal site for DNA intercalation to occur. Alkylation was observed, however, with all compounds at the guanine-rich sequence 5'-CGGGGG (bases 536-540) with the anthraquinones preferring alkylation of Gs at the 5' terminus of the G-tract and mechlorethamine the middle Gs. There was no apparent difference in sequence selectivity between alchemix and the three novel compounds ICT2901, ICT2902, and ICT2903 although qualitative differences in reactivity were evident. For example, compounds ICT2902 and ICT2903 with butyl (n = 3) or pentyl (n = 4) linkers respectively, revealed more intense bands at several alkylation sites including at base positions 536-540. None of the four agents was shown to cause DNA interstrand crosslinking in concentration-dependent (0.1-100 nM) experiments using a gel-based electrophoretic assay ( Figure S1 , Supporting Information).
Figure 2
DNA thermal denaturation studies
Reactivity of the four anthraquinones towards double-stranded DNA was assessed by measuring their capacity to modify the melting behavior (T m ) of calf thymus DNA. Using a 5:1 (50 µM DNA:10 µM compound) ratio and analysis of the "instant" (t = 0) DNA binding, the compounds were found to shift the DNA melting curve moderately (∆T m = 6.5-14.8˚C) ( Table 1) . Interestingly, notable differences in their DNA binding mode became apparent when studying time-dependent incubations at 37 °C for up to 24 h. Alchemix (n = 1) and ICT2901 (n = 2) exhibited the most stable interactions with DNA; the ∆T m observed at t = 0 (11.0 and 14.8 °C, respectively) decreased only slightly after 24 h. In contrast, ICT2902 (n = 3) and ICT2903 (n = 4), compounds with the longer carbon sidechains, were less effective in stabilizing the DNA duplex at the onset of the experiment (∆T m ≤ 7 °C) but over the course of 24 h incubation, ∆T m decreased in a near-linear fashion to zero (supporting information, Figure S2 ).
Table 1
Inhibition of topo IIα activity
The ability of the four compounds to inhibit topo IIα was measured using catenated kinetoplast DNA. The experiments was carried out as previously described using the anthraquinone-based clinical prodrug AQ4N and its metabolite AQ4 (topo IIα inhibitor) as negative and positive controls respectively [22] . All compounds were shown to completely inhibit topo IIα at 2.5 µM but at lower concentrations a dose-response was observed. Figure 3 shows that both ICT2902 and ICT2903 prevent the catenated kinetoplast DNA in migrating at 100 nM indicative of topo II inhibition. In contrast, alchemix is not able to inhibit the formation of individual DNA circles and intermediate-sized catenated complexes whereas ICT2901 partly prevents decatenation.
Figure 3
Chemosensitivity
The response of cell lines to alchemix and its analogues are presented in Tables 2 and 3 . (Table   3 ). This contrast sharply with doxorubicin, which was significantly (> 45 fold) less active against MCF-7/adr cells (Table 3 ). ICT2902 was equitoxic against both cell lines whereas (Table 3) . Table 2 Table 3 3.
Cell Cycle
The effect on cell cycle progression was investigated by flow cytometry in the HCT116 
Repair of DNA adducts in CHO cell lines
To establish the roles of DNA repair mechanisms in repairing adducts generated by the anthraquinones, a panel of Chinese hamster ovary (CHO) cell lines, with specific defects in DNA excision repair was employed. The sensitivity of the CHO cells to the anthraquinones was assessed using the DRAG assay [20] . Table 4 shows the sensitivity of the wild-type (AA8) and the DNA-defective repair CHO cell lines mutants to the respective anthraquinones after 120 h exposure to increasing concentrations of the agent. Increased sensitivity for the three compounds tested (alchemix, ICT2901 and ICT2903) was observed in the UV4 cell line, which harbors a defect in the ERCC1 gene known to affect nucleotide excision repair (NER) repair pathways. In addition, alchemix was slightly more cytotoxic to cells defective in ERCC2 (2.1 fold) and XRCC1 (1.2 fold), which may be indicative of failure to repair transcription-coupled nucleotide excision repair and base excision repair (BER) respectively. Table 4 4. Discussion
Alchemix is the prototype of a class of anthraquinone derivatives with a dual mode of action that combines DNA intercalating and alkylating properties. Alchemix has previously been shown to exhibit significant growth delay against anthracycline-and cisplatin-resistant xenografts [15] . This activity is derived from DNA intercalation, mono-alkylation and inhibition of topo IIα without inter-strand DNA cross-linking [13, 15] . Furthermore, unlike a classical topo IIα inhibitor such as doxorubicin, alchemix is neither a substrate for P-gp [15, 23] nor significantly affected by the lower levels of topo IIα present in resistant A2780/adr cells [24] . This study examined the nature of DNA binding by alchemix and subsequent cellular pharmacology. To that effect three novel analogues were designed to aid the interpretation of not only the DNA binding data, but also provide insights into how DNA injury may be recognized and cause downstream activation of cell death pathways.
The results presented in this report suggest that subtle modification to the sidechain carrying the alkylating group of alchemix has a profound effect on DNA binding. The four anthraquinones were assessed for DNA binding by measuring their induced effects on the UV thermal melting profiles (∆T m ) of duplex-form CT DNA. All compounds were found to shift the DNA melting curve moderately at t = 0, however notable differences in the stabilization of the DNA duplex were evident when studied over longer incubation times (Table 1) showed a modest preference for the 5'-peripheral guanines. In contrast, the nitrogen mustard, at ~200-fold higher dose, showed a preference for alkylating the central guanines in this sequence of contiguous guanines. This selectivity is due to enhanced nucleophilicity of the G(N7) nucleophiles in this sequence and is shared by many low molecular weight electrophilic drugs [21] . As such, it is apparent that the alkylation sites of mechlorethamine were modulated by tethering the bis-chloroethylamino moiety to the anthraquinone pharmacophore, indicating that the latter directed the site of covalent bonding. The higher potency of G alkylation by the butyl and pentyl linker compounds, suggests an improved compliance with the stereoelectronic requirements of the alkylation reaction. Despite of the higher potency in alkylating DNA, no correlation to cellular potency was apparent. Taken together, the results suggest that alchemix and ICT2901 with the shorter sidechains are able to bind to DNA in such a way that a stable DNA-drug non-covalent complex is obtained.
The anthraquinones showed dose-dependent anti-proliferative activity with IC 50 <100 nM (Tables 2 and 3 ) against both sensitive and resistant HCT116 and MCF-7 human cancer cells. Generally, the anthraquinones were equitoxic after both short-term (1 h) and long-term (96 h) exposure. In contrast, doxorubicin was less active at 1 h than after 96 h in the MCF-7
cell line (≈35-fold) and the doxorubicin-resistant sub-line MCF-7/adr (≈10-fold), suggesting that the more lipophilic nature of the anthraquinones allows them to be taken up in the cells more readily than the more hydrophilic anthracycline. Significantly, after 96 h exposure, the MCF-7/adr cell line that expresses the MDR-1 phenotype was 1.6-and 4.6-fold more sensitive to alchemix and ICT2901 respectively compared with wild-type MCF-7 cells. In contrast to ICT2902 and ICT2903, alchemix and ICT2901 formed stable complexes with DNA (Table 1) , however they were shown to be less potent topo IIα inhibitors. The MCF-7/adr cell line has been shown to possess a reduction in topo IIα protein compared to the MCF-7 cell line [26] , which support why loss of activity of the two most potent topo IIα inhibitors ICT2902 and ICT2903 is observed.
The tumor suppressor p53 plays a central role in integrating various stress signals, in particular genotoxic stresses such as DNA damage, hypoxia, and oncogene activation [10, 27, 28] . It is mutated in more than 50% of human cancers [28] and has been shown to cause resistance to chemotherapy [29] . Accordingly, the development of drugs that act independently of p53 or even exploit defective p53 as a means of preferential toxicity is very important [29, 30] . The anthraquinones investigated herein are relatively unaffected by the p53 status of colorectal HCT116 cells, as only 1.5-3-fold loss of cytotoxicity was observed in the p53-null cells after 96 h. In addition, the MCF-7/adr cell line, that harbors a mutation in p53 [31] , demonstrated slightly increased sensitivity to alchemix and ICT2901. Overall results from the four cell lines investigated indicate that p53 plays a negligible part in mediating the cytotoxicity of these two agents.
DNA damage is known to elicit a multifaceted cellular response that includes activation of DNA repair pathways, cell cycle checkpoints, and programmed cell death [30] .
The latter may occur by several molecular mechanisms [32] . Apoptosis is one of the mechanisms by which chemotherapeutic agents might induce cancer cell demise [33] . There is increasing evidence that an inability to engage apoptosis can represent a resistance mechanism to cytotoxic drugs [34] . In regard to alchemix and the three analogues, it was desirable to investigate whether their cytotoxic potency was linked with apoptosis and/or necrosis. Data obtained from our studies appeared to show an SAR between increase in sidechain length of the three novel compounds (ICT2901-3), potency in DNA alkylation and increase in number of apoptotic and necrotic cells after short term (1 h) drug exposure.
Interestingly, alchemix was found to be outside this SAR, implying differences in its mechanism of action. Early analysis (3 h) of cell cycle phase perturbations may also suggest a difference in mechanism of action as a higher number of G1 cells appeared to be arrested by alchemix treatment. This ability to perturb cells in G1 phase cells in the early stages after drug treatment may add significantly to the overall efficacy of alchemix.
DNA double strand breaks (DSBs) or damage at replication forks can be detected by phosphorylation of histone 2AX variant to form γH2AX focus formation. The role of γH2AX is to recruit DNA repair and cell cycle checkpoint proteins required for the efficient processing of DNA lesions [35] . All four compounds investigated in this study caused γH2AX phosphorylation after longer recovery times (24 h and 48 h). Intriguingly, significant γH2AX phosphorylation after short-term exposure (3 h) was only observed for ICT2901. As DNA interstrand crosslinking with naked DNA did not occur (supporting information, Figure   S1 ), it is possible that the ICT2901-induced DNA damage and subsequent γH2AX phosphorylation arise after processing or signaling DNA damage.
In support for the adduct formation we observed that alchemix, ICT2901 and ICT2903 are all potentiated in the absence of the excision repair gene ERCC1, which is involved in NER, homologous recombination and inter-strand crosslink repair [36] . The UV5 cell line is defective in the XPD protein, which is involved in NER and crosslink repair [37] , but not homologous recombination [38] . Since only the UV4 and not the UV5 cell line was sensitive to ICT2901 and ICT2903, it implicates that homologous recombination is involved in the response to these agents. Indeed, the irs1SF and NM3 cell lines defective in the recombination proteins XRCC3 and XRCC9 (FANCG) were both highly resistant to ICT2901 and ICT2903.
This is in sharp contrast to the sensitivity of these cells to crosslinking agents and topo II inhibitors [39, 40] . These data demonstrate a separation of function between commonly used anti-cancer treatments and ICT2901 and ICT2903. Table: The data represent the means of two independent experiments ± SD after treatments with indicated compounds. SR = sensitivity factor (IC 50 in parent cell line/IC 50 in defective cell line). 
Figure Legends
